Eigen Therapeutics

eigentx.com →

-89%

est. 2Y upside i

HealthcareSeed

Rank

#1534

Sector

Drug Discovery

Est. Liquidity

~7Y

Data Quality

Data: Low

Eigen Therapeutics offers a high-risk, high-reward equity opportunity for a job seeker.

Last updated: March 10, 2026

Bull (15%)+400%

Eigen's proprietary platform successfully identifies and advances multiple priming therapy candidates into early clinical trials, demonstrating strong efficacy and safety. This attracts a major pharmaceutical partnership or a lucrative Series B/C round at a significantly increased valuation, pushing the company's valuation to $200M+.

Base (40%)+100%

Eigen makes steady progress in preclinical development, validating its platform and advancing one lead candidate towards IND-enabling studies. The company secures a follow-on Series A round, doubling its valuation to approximately $80M, but faces continued challenges in navigating regulatory pathways and securing further large-scale funding.

Bear (45%)-80%

Eigen encounters significant challenges in preclinical development, such as issues with compound toxicity or lack of desired biological effect, or struggles to secure sufficient follow-on funding in a competitive biotech market. This leads to a down round or inability to progress, resulting in a valuation drop to $8M or less, wiping out most common stock value due to existing liquidation preferences.

Est. time to liquidity~7.0 years

Preference Stack Risk

high

Investors hold $7M in liquidation preferences. In an exit at $40M, common shareholders would receive value after the $7M preference is paid. If the company exits at or below $7M, common shareholders would likely receive nothing.

Dilution Risk

high

Expect significant dilution from multiple future funding rounds (Series A, B, C, etc.) required to fund expensive clinical trials and drug development.

Secondary Liquidity

none

As a seed-stage company, there is currently no active secondary market for Eigen Therapeutics' equity.

Questions to Ask at the Interview

Strategic questions based on Eigen Therapeutics's data — designed to show you've done your homework.

  • 1

    “Given the high incumbent threat from large pharmaceutical companies, how is Eigen Therapeutics planning to differentiate its platform and secure its market position against potential competitive offerings or acquisitions?”

  • 2

    “With ~$930,000 in revenue and a very high capital intensity, what is the company's detailed plan for securing the necessary Series A and subsequent funding rounds to advance candidates through clinical trials?”

  • 3

    “Considering the seed stage and the long development timelines in biotech, what is the realistic timeline for a liquidity event (IPO or acquisition) for employees, and how does the company plan to manage potential dilution from future funding rounds?”

Community

Valuation Sentiment

Our model estimates -89% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.